New
HealthMore in Health →
Intercept’s INT-787 Setback Adds Pressure in Liver Disease Drug Development
Intercept Pharmaceuticals’ next-generation FXR agonist INT-787 failed a Phase 2 study, according to the supplied report, deepening pressure on a drug developer already facing another clinical setback.
Key Takeaways
- Intercept’s INT-787 failed a Phase 2 study and showed no clear evidence of benefit.
- The result appears to end the program’s path forward, according to the supplied report.
DE
DT Editorial AI··via endpoints.news